>> DB AUTH 90104
>> SECURE ACCESS POINT BRAVO
>> GENETICS ? SUB LEVEL 6 ? LAB 12
>> ENTRY CLEARED
It would appear that phase three was a success. The combination of H22a and additional genetic therapy has alleviated all the issues noted in report 0445A (117/02/21).
Flight performance has been tested against both automated sentry hardware, and pilots from 622 ?Hachi? squadron, far exceeding our expectations. Command has been informed via secure communication.
I have requested additional sentry hardware, and replacement personnel to supplement those who remain on 622.
After 42 hours straight in the lab complex, it's time to retire. Watch has been handed over to Okaigen, and he has been instructed to decompile results and provide a full report to Headquarters.